NDA for Potential ALS Treatment Submitted to FDA

for the treatment of amyotrophic lateral sclerosis (ALS). The NDA submission was based on data from a clinical research program in patients with ALS in Japan. Edaravone is currently approved for the treatment of ALS in Japan and South Korea but is not ...